Pure Biologics SA

As of March 31, 2026, Pure Biologics SA carries a market capitalization of 32.45M, placing it among publicly traded companies globally. Its enterprise value stands at 47.87M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Pure Biologics SA has 12.24M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Pure Biologics SA maintains a current ratio of 0.09, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on August 7, 2026, Pure Biologics SA's stock has declined approximately 42.07% over the past 52 weeks. The 50-day moving average sits at 2.23, while the 200-day moving average is 3.11.

As of March 31, 2026, Pure Biologics SA holds 1.02M in cash and equivalents against 16.45M in total debt, resulting in a net debt position of 15.42M. Total book value stands at -16.39M, with working capital of -16.39M providing operational flexibility.

Pure Biologics SA's most recent stock split took place on October 30, 2025 with a 183:254 split ratio.